ClinicalTrials.gg
CompletedNCT04574362Updated Dec 14, 2023Results posted

Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

A Phase 3 interventional study of Rimegepant and Placebo in Acute Migraine, sponsored by Pfizer. Completed at 90 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,648
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
4th of 32
1,648 · median 618
Started
2020
the only one that year
Phase 3
14 of 32
5 open now
Registered
8th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 3, and was the 8th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients

Read the detailed description

Biohaven Pharmaceuticals, Inc. is the agent for BioShin Limited, the sponsor of the studies in China and Korea.

03

Conditions studied

  • Acute Migraine

Browse trials for

Keywords

  • Migraine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Subject has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, Beta version including the following:

  1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age
  2. Migraine attacks, on average, lasting about 4-72 hours if untreated
  3. Not more than 8 attacks of moderate to severe intensity per month within the last 3 months
  4. Consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening period
  5. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period.
  6. Subjects on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change during the course of the study.
  7. Subjects with for use of triptans may be included provided they meet all other study entry criteria.

Key Exclusion Criteria:

  1. Subject with a history of disease
  2. Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening
  3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to being enrolled)
  4. Subject has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion might interfere with study assessments.
  5. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease that causes malabsorption
  6. The subject has a history of current or evidence of any significant and/ or unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known suspected infection, or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.
  7. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or subjects who have met criteria for any significant substance use disorder within the past 12 months from the date of the screening visit.
  8. Subjects are excluded if they have previously participated in any study of rimegepant or other experimental CGRP-antagonist study, or have been prescribed CGRP-antibodies within the last 6 months
  9. Participation in any other clinical trial while participating in this clinical trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,648 participants (actual)

Study arms

  • Active comparator
    Rimegepant 75mg

    One 75mg oral disintegration tablet

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • One 75mg orally disintegrating tablet

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose

    Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (no pain) were considered to have freedom from pain. Exact 95 percent (%) confidence interval (CI) was based on Clopper-Pearson method.

    Time frame: 2 hours post-dose

  2. Percentage of Participants Who Had Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose

    MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 2 Hours Post-dose

    Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants who reported a pain level of moderate or severe at baseline and then reported a pain level of none or mild at 2 hours post-dose, were considered to have pain relief. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 2 hours post-dose

  2. Percentage of Participants Who Functioned Normally at 2 Hours Post-dose

    Participants rated the level of disability they perceived as a result of their migraine in performing normal actions using following level of severity: normal function, mild impairment, severe impairment, or required bedrest. This outcome measure was analyzed only among those participants who reported any impairment at baseline. Percentage of participants with a response of "normal function" at the 2 hours post-dose were reported in this outcome measure.

    Time frame: 2 hours post-dose

  3. Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose

    Percentage of participants who used rescue medications within 24 hours of administration of study drug were reported in this outcome measure. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 24 hours post-dose

  4. Percentage of Participants Who Sustained Pain Freedom From 2 to 24 Hours Post-dose

    Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 2 to 24 hours post-dose

  5. Percentage of Participants Who Sustained Pain Freedom From 2 to 48 Hours Post-dose

    Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 2 to 48 hours post-dose

  6. Percentage of Participants Who Had Freedom From Pain at 15, 30, 45, 60 and 90 Minutes Post-dose

    Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Percentage of participants who reported a pain level of moderate or severe just before taking study treatment and then reported a pain level of none at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 15, 30, 45, 60 and 90 minutes post-dose

  7. Percentage of Participants Who Had Freedom From MBS at 15, 30, 45, 60 and 90 Minutes Post-dose

    MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 15, 30, 45, 60 and 90 minutes post-dose

  8. Percentage of Participants With Pain Relapse

    Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. This outcome measure was analyzed only in those participants who were pain free at 2 hours post-dose. Percentage of participants who were pain free at 2 hours post-dose and then had a migraine of any pain severity (score 2 or 3 on the 4-point scale) within 48 hours after administration of study drug were considered to have pain relapse. Exact 95% CI was based on Clopper-Pearson method.

    Time frame: 2 Hours to 48 Hours Post-dose

07

Results

Posted Dec 14, 2023

Participant flow

Overall, 1648 participants were enrolled and screened. A total of 217 participants were screen failures. Only 1431 participants were randomized. Out of 1431 participants, only 1342 participants were treated.

Participant flow — Overall Study
MilestoneRimegepant 75 Milligram (mg)Placebo
Started716715
Treated668674
Completed709704
Not completed711
Withdrew: Other05
Withdrew: Covid-1901
Withdrew: Adverse event11
Withdrew: Withdrawal by subject24
Withdrew: Participant anxious to go to their hometown and withdrew from study10
Withdrew: Participant refused to come to the hospital10
Withdrew: Participant refused the visit10
Withdrew: Participant quit early because of business trip10

Outcome measures

PrimaryPercentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose

Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (no pain) were considered to have freedom from pain. Exact 95 percent (%) confidence interval (CI) was based on Clopper-Pearson method.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose19.8 (16.9 to 23.1)10.7 (8.5 to 13.3)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 9.2 · 95% CI 5.4 to 13.0Risk difference and associated 95 percent (%) confidence interval (CI) were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
PrimaryPercentage of Participants Who Had Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose

MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants Who Had Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose50.5 (46.6 to 54.3)35.8 (32.1 to 39.5)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 14.8 · 95% CI 9.6 to 20.0Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants With Pain Relief at 2 Hours Post-dose

Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants who reported a pain level of moderate or severe at baseline and then reported a pain level of none or mild at 2 hours post-dose, were considered to have pain relief. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 2 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants With Pain Relief at 2 Hours Post-dose66.5 (62.8 to 70.1)48.5 (44.7 to 52.4)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 18.1 · 95% CI 13.0 to 23.3Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants Who Functioned Normally at 2 Hours Post-dose

Participants rated the level of disability they perceived as a result of their migraine in performing normal actions using following level of severity: normal function, mild impairment, severe impairment, or required bedrest. This outcome measure was analyzed only among those participants who reported any impairment at baseline. Percentage of participants with a response of "normal function" at the 2 hours post-dose were reported in this outcome measure.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Functioned Normally at 2 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants Who Functioned Normally at 2 Hours Post-dose40.7 (36.6 to 45.0)23.8 (20.3 to 27.6)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 16.9 · 95% CI 11.4 to 22.3Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose

Percentage of participants who used rescue medications within 24 hours of administration of study drug were reported in this outcome measure. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose8.4 (6.4 to 10.8)20.0 (17.1 to 23.3)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): -11.5 · 95% CI -15.0 to -8.0Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants Who Sustained Pain Freedom From 2 to 24 Hours Post-dose

Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Sustained Pain Freedom From 2 to 24 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants Who Sustained Pain Freedom From 2 to 24 Hours Post-dose15.6 (12.9 to 18.6)7.9 (5.9 to 10.2)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 7.7 · 95% CI 4.3 to 11.2Risk differences and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants Who Sustained Pain Freedom From 2 to 48 Hours Post-dose

Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Sustained Pain Freedom From 2 to 48 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants Who Sustained Pain Freedom From 2 to 48 Hours Post-dose14.9 (12.2 to 17.8)7.1 (5.3 to 9.3)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference: 7.7 · 95% CI 4.4 to 11.0Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants Who Had Freedom From Pain at 15, 30, 45, 60 and 90 Minutes Post-dose

Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Percentage of participants who reported a pain level of moderate or severe just before taking study treatment and then reported a pain level of none at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
15, 30, 45, 60 and 90 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Freedom From Pain at 15, 30, 45, 60 and 90 Minutes Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
15 minutes post-dose0.8 (0.2 to 1.7)1.5 (0.7 to 2.7)
30 minutes post-dose1.1 (0.4 to 2.2)1.0 (0.4 to 2.1)
45 minutes post-dose3.3 (2.1 to 5.0)2.2 (1.3 to 3.6)
60 minutes post-dose6.8 (5.0 to 8.9)4.5 (3.0 to 6.3)
90 minutes post-dose12.3 (9.9 to 15.1)7.1 (5.3 to 9.3)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2057 (Nominal p-value) · Risk difference: -0.7 · 95% CI -1.9 to 0.4Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9702 (Nominal p-value) · Risk difference (rd): 0.0 · 95% CI -1.1 to 1.1Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2419 (Nominal p-value) · Risk difference (rd): 1.0 · 95% CI -0.7 to 2.8Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0597 (Nominal p-value) · Risk difference (rd): 2.4 · 95% CI -0.1 to 4.8Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0012 (Nominal p-value) · Risk difference (rd): 5.2 · 95% CI 2.1 to 8.4Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants Who Had Freedom From MBS at 15, 30, 45, 60 and 90 Minutes Post-dose

MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
15, 30, 45, 60 and 90 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Freedom From MBS at 15, 30, 45, 60 and 90 Minutes Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
15 minutes post-dose10.2 (8.0 to 12.8)11.1 (8.9 to 13.7)
30 minutes post-dose16.8 (14.1 to 19.9)14.8 (12.2 to 17.7)
45 minutes post-dose24.2 (21.0 to 27.6)19.9 (16.9 to 23.1)
60 minutes post-dose31.1 (27.6 to 34.7)24.8 (21.6 to 28.2)
90 minutes post-dose41.4 (37.7 to 45.3)31.8 (28.2 to 35.4)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6809 (Nominal p-value) · Risk difference (rd): -0.7 · 95% CI -3.9 to 2.5Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2586 (Nominal p-value) · Risk difference (rd): 2.2 · 95% CI -1.6 to 6.0Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0421 (Nominal p-value) · Risk difference (rd): 4.5 · 95% CI 0.2 to 8.8Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0066 (Nominal p-value) · Risk difference (rd): 6.6 · 95% CI 1.8 to 11.3Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0002 (Nominal p-value) · Risk difference (rd): 9.9 · 95% CI 4.8 to 14.9Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.
SecondaryPercentage of Participants With Pain Relapse

Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. This outcome measure was analyzed only in those participants who were pain free at 2 hours post-dose. Percentage of participants who were pain free at 2 hours post-dose and then had a migraine of any pain severity (score 2 or 3 on the 4-point scale) within 48 hours after administration of study drug were considered to have pain relapse. Exact 95% CI was based on Clopper-Pearson method.

Time frame:
2 Hours to 48 Hours Post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relapse
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants With Pain Relapse25.0 (17.9 to 33.3)33.3 (22.7 to 45.4)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1148 (Nominal p-value) · Risk difference (rd): -10.4 · 95% CI -23.5 to 2.8Risk difference and associated 95% CI were calculated from Mantel-Haenszel test, stratified by use of prophylactic medication and country. The risk difference was tested at a two-sided alpha level of 0.05.

Adverse events

Collected over Up to 7 days post-dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rimegepant 75 mg0/668 (0%)1/668 (0.1%)92/668 (13.8%)
Placebo0/674 (0%)2/674 (0.3%)94/674 (13.9%)
Most frequent serious events
Most frequent serious events
EventRimegepant 75 mgPlacebo
InfectionInfections and infestations1/6680/674
HaemoperitoneumGastrointestinal disorders0/6681/674
Decreased embryo viabilityInjury, poisoning and procedural complications0/6681/674
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/6681/674
Most frequent other events
Showing 10 of 93
Most frequent other events
EventRimegepant 75 mgPlacebo
NauseaGastrointestinal disorders7/66818/674
Protein urine presentInvestigations8/6687/674
Urinary tract infectionInfections and infestations5/6688/674
Blood creatine phosphokinase increasedInvestigations5/6683/674
AnaemiaBlood and lymphatic system disorders2/6685/674
ProteinuriaRenal and urinary disorders4/6681/674
PhotophobiaEye disorders4/6683/674
VomitingGastrointestinal disorders1/6684/674
Upper respiratory tract infectionInfections and infestations3/6684/674
Blood urine presentInvestigations3/6682/674

Baseline characteristics

Baseline analysis population included all treated participants (all enrolled participants who took either of the study drug).

Age, Continuous
Age, Continuous(Years)Rimegepant 75 mgPlaceboTotal
Mean37.8 ± 10.1337.7 ± 10.7037.8 ± 10.42
Sex: Female, Male
Sex: Female, Male(Participants)Rimegepant 75 mgPlaceboTotal
Female5265631089
Male142111253
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Rimegepant 75 mgPlaceboTotal
Count of participants——0
08

Study locations

90 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233030, China
  • Anhui provincal Hospital
    Hefei, Anhui 230001, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Lu'An People's Hospital
    Lu'an, Anhui 237011, China
  • The People's Hospital of Xuancheng City
    Xuancheng, Anhui 242299, China
  • Chinese PLA General Hospital
    Beijing, Beijing 100039, China
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Beijing Friendship Hospital,Capital Medical University
    Beijing, Beijing 100050, China
  • Chongqing Emergency Medical Center
    Chongqing, Chongqing 400014, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400042, China
  • Chonggang General Hospital
    Chongqing, Chongqing 400080, China
  • Chongqing Three Gorges Central Hospital
    Chongqing, Chongqing 404199, China
  • Fujian medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • The 900th Hospital of Joint Logistics Support Force, PLA
    Fuzhou, Fujian 350025, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
  • Sun Yat-Sen Memorial Hospital of Zhongshan University
    Guangzhou, Guangdong 510120, China
  • The First Affiliated Hospital of Hainan Medical College
    Haikou, Hainan 570102, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061017, China
  • Henan University of Science and Technology First Affiliated Hospital
    Luoyang, Henan 471003, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Zhengzhou People's Hospital
    Zhengzhou, Henan 450014, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Huanggang Central Hospital
    Huanggang, Hubei 438099, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
  • Taihe Hospital
    Shiyan, Hubei 442000, China
  • Wuhan Fourth hospital
    Wuhan, Hubei 430034, China
  • Renmin Hospital Of Wuhan University
    Wuhan, Hubei 430060, China
  • Wuhan Third Hospital
    Wuhan, Hubei 430073, China
  • Changsha Central Hospital
    Changsha, Hunan 410004, China
  • The Second Xiangya Hospital Of Central South University
    Changsha, Hunan 410011, China
  • The Third Xiangya Hospital Of Central South University
    Changsha, Hunan 410013, China
  • The Central Hospital of Shaoyang
    Shaoyang, Hunan 422099, China
  • The First People's Hospital of Yueyang
    Yueyang, Hunan 414000, China
  • Zhuzhou Central Hospital
    Zhuzhou, Hunan 412007, China
  • Zigong First People's Hospital
    Sichuan, Igong 643000, China
  • The first affiliated hospital of Baotou medical college of Inner Mongolia university of science and technology
    Baotou, Inner Mongolia 014010, China
  • Affiliated Hospital of Chifeng University
    Chifeng, Inner Mongolia 024050, China
  • Inner Mongolia People's Hospital
    Hohhot, Inner Mongolia 010017, China
  • The Second People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222023, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210028, China
  • Nanjing Brain Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital With Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • Sir Run Run Hospital, Nanjing Medical University
    Nanjing, Jiangsu 211112, China
  • Wuxi Integrated Traditional Chinese and Western Medicine Hospital
    Wuxi, Jiangsu 214000, China
  • Wuxi people's Hospital
    Wuxi, Jiangsu 214043, China
  • The Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • 1st Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130041, China
  • General Hospital of Northern Theater Command
    Shenyang, Liaoning 110015, China
  • General Hospital of Ningxia Medical Hospital
    Yinchuan, Ning Xia 750003, China
  • The First People's Hospital of Yinchuan
    Yinchuan, Ningxia 750001, China
  • Baoji Central Hospital
    Baoji, Shaanxi 721008, China
  • Xi'an Gaoxin Hospital Co., Ltd
    Xi'an, Shaanxi 710000, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • Shaanxi Provincial People' Hospital
    Xi'an, Shaanxi 710068, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, Shaanxi 710077, China
  • Yan'an University Xianyang Hospital Co., Ltd
    Xianyang, Shaanxi 712000, China
  • Shandong Provincial Qianfoshan Hospital
    Jinan, Shandong 250013, China
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong 272029, China
  • Liaocheng People's Hospital
    Liaocheng, Shandong 252004, China
  • Qingdao Central Hospital
    Qingdao, Shandong 266042, China
  • Zaozhuang Municipal Hospital
    Zaozhuang, Shandong 277102, China
  • Shanghai East Hospital
    Shanghai, Shanghai 200120, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi 046099, China
  • The Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030000, China
  • First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Nankai University, Tianjin Union Medical Center
    Tianjin, Tianjin 300121, China
  • Tianjin Huanhu Hospital
    Tianjin, Tianjin 300222, China
  • The Fifth Affiliated Hospital of Xinjiang Medical University
    Xinjiang, Uramqi 830011, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Xinjiang, Wulumuqi 830001, China
  • The Second Affiliated Hospital of Xinjiang Medical University
    Xinjiang, Wulumuqi 830018, China
  • The Second Affiliated hospital of Kunming Medical University
    Kunming, Yunnan 650101, China
  • Ruian People's Hospital
    Rui'an, Zhejiang 325299, China
  • Chuncheon Sacred Heart Hospital
    Chuncheon, Gangwon 24253, Korea, Republic of
  • Inje University Ilsan Paik Hospital
    Goyang-si, Gyeonggi-do 10380, Korea, Republic of
  • Dongtan Sacred Heart Hospital
    Hwaseong-si, Gyeonggi-do 18450, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Nowon Eulji Medical Center
    Seoul, 01830, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Kangdong Sacred Heart Hospital
    Seoul, 05355, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Ewha Womans University Medical Center
    Seoul, 07804, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 08308, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2021, 13 months.

Results were first posted in Dec 2023, 2 years after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 13 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2020
First posted
Oct 5, 2020
StartActual
Oct 22, 2020
Primary completionActual
Nov 24, 2021
CompletionActual
Dec 16, 2021
Results first posted
Dec 14, 2023
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04574362
Lead sponsor
Pfizer
Collaborators
BioShin Limited
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Oct 22, 2020
Primary completion
Nov 24, 2021
Completion
Dec 16, 2021
Results posted
Dec 14, 2023
Last update
Dec 14, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion